Piqray, an anticancer drug targeting the PIK3CA gene, can be prescribed at a general hospital. According to related industries, Novartis' Piqray passed the Drug Committee of 18 medical institutions nationwide, including Samsung Medical Center, Seoul St. Mary's Hospital, and Seoul Asan Medical Center, as well as Bundang Medical Center and Korea University Anam Hospital. Piqray, approved in Korea in May last year, is a PIK3CAα inhibitor that blocks excessive activity of the PI3K pathway by inhibiting overactivation of PI3K-α due to PI3CA gene mutation, and is a target anticancer drug prescribed in combination with Faslodex in previously failed HR+/HER2-transitive and progressive breast cancer patients. Howeve